|
DE69729880T3
(de)
*
|
1996-12-24 |
2012-05-10 |
Biogen Idec Ma Inc. |
Stabile flüssige interferon-zubereitungen
|
|
US20030190307A1
(en)
|
1996-12-24 |
2003-10-09 |
Biogen, Inc. |
Stable liquid interferon formulations
|
|
DK1017413T4
(da)
*
|
1997-09-23 |
2008-03-25 |
Rentschler Biotech Gmbh |
Flydende formulering af interferon-beta
|
|
CA2375779A1
(en)
*
|
1999-05-31 |
2000-12-07 |
Mitsubishi Chemical Corporation |
Lyophilized hgf preparation
|
|
US6887462B2
(en)
|
2001-04-09 |
2005-05-03 |
Chiron Corporation |
HSA-free formulations of interferon-beta
|
|
UY27373A1
(es)
*
|
2001-07-09 |
2003-02-28 |
Schering Ag |
Formulaciones de interferón beta-humano
|
|
JP2005530683A
(ja)
|
2001-12-21 |
2005-10-13 |
ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト |
第vii因子ポリペプチドの液体組成物
|
|
JP4340540B2
(ja)
*
|
2002-01-18 |
2009-10-07 |
旭化成ファーマ株式会社 |
可溶性トロンボモジュリン高濃度含有製剤
|
|
CN101912601B
(zh)
|
2002-06-21 |
2012-08-29 |
诺和诺德医疗保健公司 |
因子vii多肽的稳定化固体组合物
|
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
|
US7897734B2
(en)
|
2003-03-26 |
2011-03-01 |
Novo Nordisk Healthcare Ag |
Method for the production of proteins
|
|
TWI272948B
(en)
*
|
2003-05-01 |
2007-02-11 |
Ares Trading Sa |
HSA-free stabilized interferon liquid formulations
|
|
AR044302A1
(es)
|
2003-05-13 |
2005-09-07 |
Ares Trading Sa |
Formulaciones con proteinas liquidas estabilizadas en recipientes farmaceuticos
|
|
KR20060015574A
(ko)
|
2003-05-23 |
2006-02-17 |
노보 노르디스크 헬스 케어 악티엔게젤샤프트 |
용액 중 단백질 안정화
|
|
CN1318087C
(zh)
*
|
2003-06-06 |
2007-05-30 |
北京三诺佳邑生物技术有限责任公司 |
去白蛋白神经生长因子制剂
|
|
EP1656158B1
(en)
|
2003-08-14 |
2016-03-09 |
Novo Nordisk Health Care AG |
Liquid, aqueous pharmaceutical composition of factor vii polypeptides
|
|
CA2546280A1
(en)
*
|
2003-11-13 |
2005-06-09 |
Alza Corporation |
Composition and apparatus for transdermal delivery
|
|
EP1532983A1
(en)
*
|
2003-11-18 |
2005-05-25 |
ZLB Bioplasma AG |
Immunoglobulin preparations having increased stability
|
|
EP2311437A1
(en)
|
2003-12-19 |
2011-04-20 |
Novo Nordisk Health Care AG |
Stabilised compositions of factor VII polypeptides
|
|
EA012281B1
(ru)
*
|
2004-06-01 |
2009-08-28 |
Арес Трейдинг С.А. |
Способ стабилизации белков
|
|
BRPI0514408B8
(pt)
*
|
2004-08-24 |
2021-05-25 |
Asubio Pharma Co Ltd |
preparação liquida de peptídeo fisiologicamente ativo
|
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
|
DE602005011321D1
(de)
*
|
2004-11-10 |
2009-01-08 |
Novartis Vaccines & Diagnostic |
Deamidiertes interferon-beta
|
|
EP1845925B1
(en)
*
|
2005-01-12 |
2016-08-24 |
Biogen MA Inc. |
Method for delivering interferon-beta
|
|
AU2006206272A1
(en)
*
|
2005-01-21 |
2006-07-27 |
Alza Corporation |
Therapeutic peptide formulations for coating microneedles with improved stabitity containing at least one counterion
|
|
EP2264162A1
(en)
|
2005-07-02 |
2010-12-22 |
Arecor Limited |
Stable aqueous systems comprising proteins
|
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
BRPI0711558A2
(pt)
|
2006-05-04 |
2011-11-08 |
Boeringer Ingelheim Internat Gmbh |
polimorfos
|
|
CA3123813C
(en)
*
|
2007-12-04 |
2024-10-08 |
Remedy Pharmaceuticals, Inc. |
IMPROVED GLIBENCLAMIDE FORMULATIONS AND RELATED FREEZE-DRYING METHODS, AND FREEZE-DRY SATE PRODUCED THUS
|
|
RS52417B
(sr)
|
2007-12-20 |
2013-02-28 |
Merck Serono S.A. |
Formulacije peg-interferona-beta
|
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
|
ES2531657T3
(es)
|
2008-05-01 |
2015-03-18 |
Arecor Limited |
Formulación de una proteína
|
|
EP2328607A1
(en)
|
2008-07-16 |
2011-06-08 |
Arecor Limited |
Stable formulation of a therapeutic protein
|
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
|
AU2009290911A1
(en)
|
2008-09-10 |
2010-03-18 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
|
DE102008051574A1
(de)
|
2008-10-14 |
2010-04-15 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Verfahren zur Herstellung von Interferon-beta und deren Varianten
|
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
|
EP2382216A1
(en)
|
2008-12-23 |
2011-11-02 |
Boehringer Ingelheim International GmbH |
Salt forms of organic compound
|
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
|
DE102009032179A1
(de)
|
2009-07-07 |
2011-01-13 |
Biogenerix Ag |
Verfahren zur Reinigung von Interferon beta
|
|
EA034869B1
(ru)
|
2009-11-27 |
2020-03-31 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
|
|
DK2531218T3
(en)
|
2010-02-04 |
2019-04-01 |
Csl Behring Ag |
immunoglobulin
|
|
EP2361636A1
(en)
|
2010-02-26 |
2011-08-31 |
CSL Behring AG |
Immunoglobulin preparation and storage system for an immunoglobulin preparation
|
|
DE102010011430A1
(de)
*
|
2010-03-15 |
2011-09-15 |
Kurt Koch |
Verfahren für den Bau des Nullenergiehauses in Schalenbauweise durch Ausschäumen aller Wände, Decken und Bedachung
|
|
MX341025B
(es)
|
2010-05-05 |
2016-08-04 |
Boehringer Ingelheim Int Gmbh * |
Terapia de combinacion.
|
|
PH12012502524A1
(en)
|
2010-06-24 |
2014-02-10 |
Boehringer Ingelheim Int |
Diabetes therapy
|
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
|
EP2649993B1
(en)
|
2010-12-09 |
2017-04-05 |
Maruishi Pharmaceutical Co., Ltd. |
Stabilizer of acetaminophen
|
|
CA2846786C
(en)
|
2011-03-15 |
2022-05-17 |
Biogen Idec Inc. |
Method for reducing flu-like symptoms associated with intramuscular administration of interferon using a fast titration escalating dosing regimen
|
|
EP3517539B1
(en)
|
2011-07-15 |
2022-12-14 |
Boehringer Ingelheim International GmbH |
Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
|
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
|
MX2014012461A
(es)
*
|
2012-04-19 |
2015-01-12 |
Bard Inc C R |
Soluciones intravenosas con estabilidad de ph mejorada bajo esterilizacion con oxido de etileno.
|
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
|
ITMI20120913A1
(it)
*
|
2012-05-28 |
2013-11-29 |
Nicoletta Maxia |
Uso della n-acetil-5-metossitriptamina o suoi analoghi per favorire il meccanismo di impianto dell' embrione, e relative composizioni e mezzi di coltura
|
|
CN103143000B
(zh)
*
|
2013-03-07 |
2014-11-05 |
安徽安科生物工程(集团)股份有限公司 |
一种重组人干扰素α2b制剂
|
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
|
JP2014208669A
(ja)
*
|
2014-06-17 |
2014-11-06 |
株式会社スリー・ディー・マトリックス |
タンパク質の凝集抑制剤
|
|
CN121371151A
(zh)
|
2014-12-03 |
2026-01-23 |
瑞士杰特贝林生物制品有限公司 |
具有增加的稳定性的包含免疫球蛋白的药物产品
|
|
CN109310697A
(zh)
|
2016-06-10 |
2019-02-05 |
勃林格殷格翰国际有限公司 |
利格列汀和二甲双胍的组合
|
|
KR101943160B1
(ko)
*
|
2016-10-06 |
2019-01-30 |
에이비온 주식회사 |
인터페론 베타 변이체의 안정화 제제
|
|
MD3672631T3
(ro)
|
2017-08-22 |
2023-09-30 |
Biogen Ma Inc |
Compoziții farmaceutice conținând anticorpi anti-beta amiloidici
|
|
KR102731889B1
(ko)
*
|
2019-07-18 |
2024-11-19 |
에이비온 주식회사 |
2당화된 인터페론-베타 단백질의 정제 방법
|
|
CN110714051B
(zh)
*
|
2019-11-20 |
2023-04-07 |
迈克生物股份有限公司 |
蛋白c活性测定试剂盒
|
|
US20230159605A1
(en)
*
|
2020-04-29 |
2023-05-25 |
Abion Inc. |
Human interferon-beta variant with double mutation and method for improving stability of human interferon-beta variant
|
|
EP4313211A1
(en)
*
|
2021-03-30 |
2024-02-07 |
SCHOTT Pharma Schweiz AG |
System for low-temperature storage of a pharmaceutical composition, liquid composition, method and uses
|
|
CN114177273B
(zh)
*
|
2021-11-29 |
2024-05-28 |
苏州人本药业有限公司 |
一种含有神经毒素的液体制剂及其制备方法
|
|
JP2025501169A
(ja)
*
|
2021-12-27 |
2025-01-17 |
エナラーレ セラピューティクス インコーポレイテッド |
呼吸刺激薬非経口製剤
|